pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

hemoshear-therapeutics PRESS RELEASE ARCHIVE

Nov 17, 2022

HemoShear Therapeutics to Participate in Piper Sandler Healthcare Conference

Oct 18, 2022

HemoShear Therapeutics to Participate in SVB Leerink Securities Biopharma Private Company Connect

Sep 21, 2022

HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics' Gout Discovery Pipeline

Aug 25, 2022

HemoShear Therapeutics Appoints Brian Wamhoff, PhD, Interim Chief Executive Officer

Jun 7, 2022

OpenBench Assigns Two AI-Discovered Series to HemoShear Therapeutics

Dec 14, 2021

HemoShear Therapeutics Appoints Patrick Horn, MD, PhD, Chief Medical Officer

Nov 16, 2021

HemoShear Therapeutics Identifies Second Novel Target to Treat NASH Through Successful Collaboration with Takeda

Oct 5, 2021

OpenBench and HemoShear Therapeutics Agree to Pursue Rare Disease Target Using Artificial Intelligence

Sep 21, 2021

HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline

Jul 22, 2021

HemoShear Therapeutics Announces First Two Patients Dosed in Phase 2 Study of Oral Small Molecule HST5040 for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

Apr 21, 2021

HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout

Feb 10, 2021

HemoShear Therapeutics Raises $40 Million in Series A Financing to Advance Rare Disease Portfolio

Dec 16, 2020

HemoShear Therapeutics' HST5040 Receives U.S. Orphan Drug Designations for Treatment of Methylmalonic Acidemia and Propionic Acidemia

Dec 10, 2020

HemoShear Therapeutics Identifies Novel Drug Target to Treat NASH in Drug Discovery Partnership with Takeda

Oct 21, 2020

HemoShear Therapeutics Enters into Rare Liver Disease Research Collaboration with Takeda

Jul 28, 2020

HemoShear Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for HST5040 to Treat Methylmalonic Acidemia and Propionic Acidemia

Jul 9, 2020

HemoShear Therapeutics Achieves Milestone in Exclusive Drug Discovery Collaboration with Horizon Therapeutics in Gout

Jun 24, 2020

HemoShear Therapeutics Receives FDA Clearance of IND for Phase 2 Study of its Investigational Drug HST5040 for the Treatment of Methylmalonic Acidemia and Propionic Acidemia

Sep 25, 2019

HemoShear Therapeutics Appoints Brian A. Johns, PhD, Chief Scientific Officer

Aug 6, 2019

HemoShear Therapeutics to Present at Wedbush PacGrow Healthcare Conference

Jun 19, 2019

HemoShear Therapeutics Names Biopharma Veteran Kathleen M. Metters, PhD, to Board of Directors

Mar 20, 2019

Takeda and HemoShear Therapeutics Extend Exclusive Drug Discovery Partnership in Liver Diseases

Mar 6, 2019

HemoShear Therapeutics Physiological Human Tumor Model Published in Lab on a Chip Journal

Jan 3, 2019

Horizon Pharma plc and HemoShear Therapeutics Enter into Exclusive Drug Discovery Collaboration in Gout

Dec 4, 2018

Carnot BioSciences, A Spin Off Of SmartZyme BioPharma, And HemoShear Therapeutics Partner To Develop Protein-Based Therapeutics For Rare Metabolic Diseases

Oct 17, 2017

Takeda and HemoShear Therapeutics Enter into Exclusive Drug Discovery Partnership in Liver Diseases

Jan 5, 2017

HemoShear Therapeutics Appoints John E. Reardon as Head of Research and Development

Jan 11, 2016

HemoShear Therapeutics Announces Next Stage of Safety Collaboration with Pfizer Inc.

Jan 6, 2016

HemoShear Therapeutics Races Toward Discovery of Treatments for Children's Rare Diseases

Nov 24, 2015

HemoShear Therapeutics Names H. Thomas Watkins to Board of Directors

Jul 9, 2015

HemoShear Therapeutics Names Robert Gould to Board of Directors

Jul 9, 2015

HemoShear Therapeutics Names Robert Gould to Board of Directors

Google Analytics Alternative